상세 보기
초록
Objectives: With the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), sequential therapy could potentially render EGFR mutation-positive non-small cell lung cancer a chronic disease in some patients. In this retrospective analysis of EGFR mutation-positive (De119/L858R) patients receiving first-line afatinib in LUX-Lung 3, 6, and 7, we assessed uptake of, and outcomes following, subsequent therapies including the third-generation EGFR TKI, osimertinib. Methods: Post-progression therapy data were prospectively collected during follow-up. Molecular testing of tumours at progression/discontinuation of afatinib was not mandatory. Duration of subsequent therapies, and survival following osimertinib, were calculated with Kaplan-Meier estimates. Results: Among 553 patients who discontinued first-line afatinib, second-, third- and fourth-line therapy was administered in 394 (71%), 265 (48%), and 156 (28%) patients. The most common post-progression therapy was platinum-based chemotherapy (46%). Thirty-seven patients received subsequent osimertinib, 10 as second-line treatment. Median progression-free survival on afatinib in these 37 patients was 21.9 months. Median duration of osimertinib therapy was 20.2 months; median overall survival was not reached after a median follow-up of 4.7 years. Conclusions: Most patients treated with first-line afatinib received subsequent therapy. Although limited by sample size, enrichment, and a retrospective nature, data from patients who received sequential afatinib and osimertinib are encouraging, warranting further investigation.
키워드
- 제목
- Sequencing of therapy following first-line afatinib in patients with <i>EGFR</i> mutation-positive non-small cell lung cancer
- 저자
- Park, Keunchil; Bennouna, Jaafar; Boyer, Michael; Hida, Toyoaki; Hirsh, Vera; Kato, Terufumi; Lug, Shun; Mok, Tony; Nakagawa, Kazuhiko; O'Byrne, Kenneth; Paz-Ares, Luis; Schuler, Martin; Sibilotru, Denis Moro; Tan, Eng-Huat; Tanaka, Hiroshi; We, Yi-Long; Yang, James C-H; Zhang, Li; Zhou, Caicun; Maerten, Angela; Tang, Wenbo; Yamamoto, Nobuyuki
- 발행일
- 2019-06
- 유형
- Article
- 저널명
- Lung Cancer
- 권
- 132
- 페이지
- 126 ~ 131
- 언어
- ENG
- 출판사
- Elsevier BV
- 발행국가
- 아일랜드
- 분량
- 6 페이지
- ISSN
- E 1872-8332
P 0169-5002